Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2401 - 2425 of 3186 in total
Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).
Investigational
A complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Experimental
Matched Mixtures name: … aspen nutrition Omega 3-6-9
Experimental
Investigational
Matched Products: … PROTAMİN ICN 5000 IU/5ML IV KULLANIM İÇİN ENJEKSİYONLUK ÇÖZELTİ İÇEREN AMPUL, 50 ADET …
Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January...
Investigational
Matched Iupac: … (7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy}-6,11-dihydroxy-5,7,8,9,10,12-hexahydrotetracene …
Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
Investigational
Fluprednidene acetate is a corticosteroid. It has anti-inflammatory and anti-allergic properties.
Experimental
Experimental
Matched Products: … PLASTUFER MITE 50 MG …
Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.[L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).
Investigational
Investigational
Aphidicolin is an antimitotic and antiviral metabolite of the mould Cephalosporium aphidicola. It inhibits DNA polymerase alpha and blocks DNA replication.[A259157, A259162]
Investigational
An essential amino acid that is required for the production of histamine.
Investigational
Nutraceutical
Matched Salts cas: … 13870-80-9
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 8.5% With 50% Dextrose ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML …
Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.
Nutraceutical
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 8.5% With 50% Dextrose ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML …
An essential amino acid that is physiologically active in the L-form.
Investigational
Nutraceutical
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 8.5% With 50% Dextrose ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML …
Bebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. Bebtelovimab is notable in that the...
Investigational
Withdrawn
Investigational
Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
Investigational
Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).
Investigational
Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).
Investigational
Experimental
scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Displaying drugs 2401 - 2425 of 3186 in total